Support Networks

The links listed below will connect you to sites containing information and support from professional medical organizations, hospitals, national and international Gaucher disease groups, patient support organizations, and medical centers specializing in Gaucher disease care and research.

Gauchercare.com
http://www.gauchercare.com/
A genzyme-sponsored web site created for people living with Gaucher, their friends and families, and health care professionals.

National Gaucher Foundation (USA)
http://www.gaucherdisease.org/
A national non-profit organization that funds research, offers financial assistance, promotes education and awareness, supports legislative issues and provides outreach programs.

Genetic Alliance
http://www.geneticalliance.org
The world's leading nonprofit health advocacy organization committed to transforming health through genetics.

National Organization for Rare Disorders (NORD)
http://www.rarediseases.org
A non-profit federation of voluntary health organizations dedicated to helping people with rare "orphan" diseases and assisting the organizations that serve them.

National Tay-Sachs & Allied Diseases Association
http://www.ntsad.org
An organization established to lead the fight to treat and cure Tay-Sachs, Canavan and other genetic diseases like Gaucher disease, and to support affected families and individuals in leading fuller lives.

Society for Inherited Metabolic Disorders
http://www.simd.org
A non-profit professional organization whose purpose is to promote the worldwide advancement of research and medical treatment of inherited disorders of metabolism.

Genetic Disease Foundation
http://www.geneticdiseasefoundation.org
An organization established by patients, parents and families to support research, education and the prevention of genetic diseases.

Indication & Usage

Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:

  1. anemia (low red blood cell count)
  2. thrombocytopenia (low blood platelet count)
  3. bone disease
  4. hepatomegaly or splenomegaly (enlarged liver or spleen)

Important Safety Information

Approximately 15% of patients have developed immune responses (antibodies) to Cerezyme during the first year of therapy. These patients have a higher risk of an allergic reaction (hypersensitivity). Your doctor may periodically test for the presence of antibodies. Serious allergic reactions (anaphylaxis) have been reported in less than 1% of patients. Symptoms suggestive of allergic reaction happened in approximately 7% of patients, and include itching, flushing, hives, swelling, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), and low blood pressure. If you have had an allergic reaction to Cerezyme, you and your doctor should use caution if you continue to receive treatment with Cerezyme.

High blood pressure in the arteries of the lungs (pulmonary hypertension) and pneumonia have been observed in less than 1% of patients during treatment with Cerezyme. These are also known complications of Gaucher disease regardless of treatment. If you experience symptoms such as shortness of breath or chest pain, with or without fever, contact your doctor.

Approximately 14% of patients have experienced side effects related to treatment with Cerezyme. Some of these reactions occur at the site of injection such as discomfort, itching, burning, swelling or uninfected abscess. Other side effects, each of which was reported by less than 2% of patients, include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and rapid heart rate. Temporary swelling in the legs has also been observed with drugs like Cerezyme.

Please see Full Prescribing Information (PDF).

Cerezyme has been demonstrated for over 17 years to be an effective treatment for Type 1 Gaucher disease in adults and children.